Rx Industry May Need To Inject More Funds Into R&D – GSK Exec
Executive Summary
Pharmaceutical manufacturers should consider increasing research & development investments to sustain growth, GlaxoSmithKline R&D Chairman Tachi Yamada declared during a Nov. 30 pipeline update
You may also be interested in...
Garnier’s Vision: GSK To Be “The Most R&D Intensive Company In The World”
GlaxoSmithKline appears ready to turn the typical pharmaceutical company business model on its head, with plans to significantly increase the percentage of sales spent on research & development and reduce spending on selling, general & administrative expenses
Garnier’s Vision: GSK To Be “The Most R&D Intensive Company In The World”
GlaxoSmithKline appears ready to turn the typical pharmaceutical company business model on its head, with plans to significantly increase the percentage of sales spent on research & development and reduce spending on selling, general & administrative expenses
Amgen Sizes Up Strategy: Small-Scale Acquisitions, Large-Scale R&D
Amgen's growth strategy calls for heavy investment in research & development and targeted agreements to expand its pipeline, rather than large-scale acquisitions, CEO Kevin Sharer said